Optibrium launches a metabolism prediction software platform tailored to DMPK scientists

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the launch of Semeta™, a metabolism prediction platform tailored specifically for drug metabolism and pharmacokinetics (DMPK) scientists.

Fundamental to improving a drug’s chance of clinical success, Semeta allows the accurate prediction of Phase I and II metabolic routes, sites, products, and liabilities in early drug discovery, with superior precision to comparable software.

DMPK scientists are responsible for interpreting metabolite-ID experiments, a task that can be made easier with sensitive and precise in silico metabolite prediction.

However, many of the currently available tools suffer from significant metabolite overprediction, resulting in wasted time, effort and resources as researchers have to filter through predicted metabolites that are then not reported experimentally. Tackling this key challenge, Optibrium’s Semeta offers high sensitivity and superior precision to improve workflow efficiency.

Semeta enables more precise metabolite prediction across the key enzymes involved in human Phase I and II metabolism. It also includes models for rat, mouse, and dog cytochrome P450 (CYP), the most important enzyme family involved in drug metabolism.

This enables comparison between human, rat, mouse, and dog predictions, supporting the selection of the most appropriate preclinical species for in vivo efficacy, PK, and toxicology studies.

Semeta employs models that are based on a fundamental understanding of the reaction mechanisms leading to drug metabolism, using quantum mechanics and machine learning to indicate potential sites of metabolism for each compound by each enzyme. In addition, classification models give a fast indication of which enzymes or isoforms are most likely to metabolize a compound.

In Semeta, these models are integrated into a user-friendly, intuitive, cloud-based environment with various tools to support data management and sharing. The software allows users to surface powerful metabolism data to improve their likelihood of compound success.

“Semeta is the culmination of years of extensive peer-reviewed metabolism research, and we are delighted to offer this accurate and robust new software to the DMPK community. We believe Semeta is excellently placed to tackle the many challenges of drug metabolism, and provide an accurate picture of Phase I and II metabolism.”

Dr Peter Hunt, Director of Computational Chemistry at Optibrium

For further information on Optibrium or Semeta, please visit https://optibrium.com/semeta, contact [email protected] or call +44 1223 815900.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2024, February 27). Optibrium launches a metabolism prediction software platform tailored to DMPK scientists. News-Medical. Retrieved on April 14, 2024 from https://www.news-medical.net/news/20240227/Optibrium-launches-a-metabolism-prediction-software-platform-tailored-to-DMPK-scientists.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium launches a metabolism prediction software platform tailored to DMPK scientists". News-Medical. 14 April 2024. <https://www.news-medical.net/news/20240227/Optibrium-launches-a-metabolism-prediction-software-platform-tailored-to-DMPK-scientists.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium launches a metabolism prediction software platform tailored to DMPK scientists". News-Medical. https://www.news-medical.net/news/20240227/Optibrium-launches-a-metabolism-prediction-software-platform-tailored-to-DMPK-scientists.aspx. (accessed April 14, 2024).

  • Harvard

    Optibrium Ltd.. 2024. Optibrium launches a metabolism prediction software platform tailored to DMPK scientists. News-Medical, viewed 14 April 2024, https://www.news-medical.net/news/20240227/Optibrium-launches-a-metabolism-prediction-software-platform-tailored-to-DMPK-scientists.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Optibrium Shows Deep Learning to Successfully Predict Human Panel-based Sensory Perception of Novel Compounds Used for Flavours and Fragrances